Добірка наукової літератури з теми "Cancer tumer"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Cancer tumer".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Cancer tumer"
Blaich, Günter, Hella Raade, and Manfred Metzler. "Modification of 7,8–benzoflavone metabolism in hamster liver and kidney microsomes by hepatic tumer inducing treatments." Carcinogenesis 11, no. 1 (1990): 95–101. http://dx.doi.org/10.1093/carcin/11.1.95.
Повний текст джерелаParsons, Heather A., Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana Abramson, et al. "Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030." Cancer Research 83, no. 5_Supplement (March 1, 2023): PD11–06—PD11–06. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd11-06.
Повний текст джерелаCho, Bong Jun, Hans H. Kim, David J. Lee, Eun Jung Choi, Yeo Hyun Hwang, Sun Ha Chun, and In Ah Kim. "MicroRNA-21 inhibitor potentiates anti-tumor effect of radiation therapy in vitro and in vivo." Tumor Microenvironment and Therapy 2, no. 1 (January 10, 2014): 1–13. http://dx.doi.org/10.2478/tumor-2014-0001.
Повний текст джерелаLavekar, G. S. "Arbud-Tumor-Cancer- a concise integrative review." Journal of Clinical Oncology Reports 1, no. 1 (January 20, 2023): 01–05. http://dx.doi.org/10.58489/2836-5062/001.
Повний текст джерелаGARCÍA CEBRIÁN, MARÍA JOSÉ, MONIKA BAUDEN, ROLAND ANDERSSON, STEFAN HOLDENRIEDER, and DANIEL ANSARI. "Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?" Anticancer Research 36, no. 9 (September 9, 2016): 4381–90. http://dx.doi.org/10.21873/anticanres.10981.
Повний текст джерелаSK, Deshmukh. "Immune Cells in the Tumor Microenvironment and Cancer Stem Cells: Interplay for Tumor Progression." Journal of Embryology & Stem Cell Research 2, no. 2 (2018): 1–2. http://dx.doi.org/10.23880/jes-16000109.
Повний текст джерелаFejzić, Hanifa. "Tumor marker CA 15-3 in breast cancer patients." Acta Medica Academica 44, no. 1 (June 2, 2015): 39–46. http://dx.doi.org/10.5644/ama2006-124.125.
Повний текст джерелаSingh, Dr Ravi Pratap. "HLA A24 Associated Tumor Immunity in HER2/neu Positive Breast Cancer." Recent Advances in Pathology & Laboratory Medicine 3, no. 2 (August 21, 2017): 13–16. http://dx.doi.org/10.24321/2454.8642.201702.
Повний текст джерелаLi, Lin, Mengyuan Li, Zehang Jiang, and Xiaosheng Wang. "ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer." Cells 8, no. 7 (July 4, 2019): 678. http://dx.doi.org/10.3390/cells8070678.
Повний текст джерелаNenciu, Adina-Elena, C. G. Nenciu, R. Fodoroiu, Florica Șandru, and M. C. Dumitrașcu. "TUMOR MARKERS IN OVARIAN CANCER." Journal of Surgical Sciences 7, no. 2 (September 1, 2020): 79–84. http://dx.doi.org/10.33695/jss.v7i2.356.
Повний текст джерелаДисертації з теми "Cancer tumer"
Lale, Shantanu Vijay. "Development of stimuli responsive polymeric nanosystems for cancer therapeutics." Thesis, IIT Delhi, 2016. http://localhost:8080/xmlui/handle/12345678/6999.
Повний текст джерелаMcGinley, Susan. "Sensitizing Tumor Response to Cancer Therapy." College of Agriculture and Life Sciences, University of Arizona (Tucson, AZ), 2008. http://hdl.handle.net/10150/622086.
Повний текст джерелаHoarau, Jessica. "Halfway Between 2D Models and Animal Models : a New Multicellular 3D Spheroid Model Organized to Study Tumor-Endothelium Interactions in Ovarian Cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS111.
Повний текст джерелаOvarian cancer (OC) is the most lethal gynecologic malignancy in developed countries and the fifth cause of death among women. OC is a heterogeneous disease, which is characterized by its late diagnosis (FIGO III and IV stages) and the importance of abdominal metastases often observed at the time of diagnosis. The mainstay of treatment involves complete cytoreductive surgery associated with platinum and taxane-based chemotherapy. Unfortunately, among patients achieving complete clinical remission after completion of initial treatment, 60% with advanced epithelial ovarian cancer (EOC) will relapse within five years.The importance of neo-angiogenesis in tumor formation, growth and dissemination has driven researchers to investigate into alternative strategies. Anti-angiogenic therapies targeting tumor vasculature are now used in combination with standard cytotoxic therapy in the treatment of EOC. Unfortunately, the progress achieved by this approach still offers limited success which can partly be explained by the heterotypic interaction between the tumor and endothelial cells. Evidence suggests a complex cross-talk between ovarian cancer cells (OCCs) and endothelial cells (ECs) that can result in the emergence of a heterogeneous tumoral and endothelial population with different sensitivity to chemotherapy and anti-angiogenic therapies leading to an increase of OCC proliferation and dissemination.The objective of the present study is to investigate the role of ECs and OCCs interactions in the proliferation and chemoresistance of EOC. To model tumor endothelium, we used our model of Akt-activated endothelial cells (E4+ECs). We demonstrated using a 2D co-culture model that activated endothelium induces increased proliferation and chemoresistance in EOC through the activation of Notch signaling. We showed that Notch receptor expression and activation are increased in co-culture and in OCCs resistant to chemotherapy.The accumulation of ascites in the abdomen of an OC patient seems to play a key role in the mechanism of OCC spreading. Detached cancer cells usually float in ascites and form multicellular spheroids. In this context, we developed a new model of organized multicellular 3D spheroid to study tumor-endothelium interactions in a model closer to in vivo conditions. We demonstrated that when cocultured in 3D condition, E4+ECs and OCCs formed organized tumor angiospheres with a core of endothelial cells surrounded by highly proliferating OCCs. We established that AKT activation in ECs was mandatory for the formation of organized angiospheres. Interestingly, in EOC patient ascites, we were able to find structures that were very similar to our angiospheres. In addition, in a retrospective cohort of 59 patients, we showed that ECs were AKT activated in EOC patients which support the importance of AKT activation in EC in EOC. Besides, we demonstrated the importance of FGF2, Pentraxin 3 (PTX3), PD-ECGF and TIMP-1 in angiosphere organization. Finally, we confirmed the role of Notch3/Jagged1 in OCCs-ECs crosstalk for OCC proliferation but also during peritoneum invasion.Altogether, our study illustrates the importance of AKT activated ECs in EOC. In a context of poor results of anti-angiogenic therapies in clinical settings, focusing on vascular normalization in pathological angiogenesis could be more efficient. While AKT is hardly targetable, the genetic characterization of tumors could potentially identify a subset of tumors with aberrant NOTCH signaling that would constitute an ideal target for specific inhibitors. As we move toward personalized and precision medicine, there might be a place for notch inhibition in advanced ovarian cancer in combination with other therapeutic strategies
Stemmer, Kerstin. "Molecular Characteristics of Kidney Cancer." [S.l. : s.n.], 2008. http://nbn-resolving.de/urn:nbn:de:bsz:352-opus-73925.
Повний текст джерелаDacheux, Estelle. "Implication de la protéine onco-suppressive BRCA1 dans la régulation de la traduction." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10077.
Повний текст джерелаBRCA1 is one of the two major genes of breast cancer susceptibility. The numerous binding partners of BRCA1 allow it to participate to several cellular pathways which globally contribute to its cell surveillance capacity. The team in which I performed my PhD identified a new bindind partner of BRCA1, the Poly(A)-Binding Protein 1 and, consequently, a new function of this tumor suppressor, namely, the translation regulation [1]. During my PhD, I studied this new function and try to elucidate if, and how, this function could participates to the BRCA1’s tumor suppressive activity. I first showed that BRCA1 is associated with the ribosomal fraction of the cell, and more precisely, with the subpolysomal fraction, which could indicate that BRCA1 participates to the initiation step of translation. Moreover, our results suggest that BRCA1 could participate to a non canonical initiation complex. Given that BRCA1 is not a canonical translation initiation factor, it is unlikely that BRCA1 regulates the translation of all mRNAs. Our hypothesis is that BRCA1 could regulate the translation of specific mRNAs involved in its various cell surveillance functions. In an attempt to identify the BRCA1 translational targets, we performed a microarray analysis of polysomes-bound mRNAs in MCF7 cells transiently expressing siRNA directed against BRCA1 or control siRNA. We found that, among the translational targets of BRCA1, many indeed encode proteins involved in the same main functions as BRCA1’s. Altogether, our results suggest that the involvement of BRCA1 in translation regulation could be another way by which BRCA1 exerts its tumor suppressor role. Moreover, the analysis of the BRCA1’s translational targets could lead to the identification of new functions for BRCA1 as well as to the discovery of new tumoral markers and therapeutic targets for the BRCA1 mutated patients
Bonneau, Claire. "Étude des mécanismes de récidive métastatique dans les cancers du sein luminaux de stade précoce : impact du microenvironnement tumoral Caractérisation moléculaire des cancers du sein en pratique clinique A subset of activated cancer associated fibroblasts is associated with distant relapse in early luminal breast cancers." Thesis, Sorbonne Paris Cité, 2018. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=2365&f=17162.
Повний текст джерелаPurpose: Early luminal breast cancers (BC) represent 70% of newly diagnosed BC. Their prognosis is generally favorable but some patients (around 5 to 10% at 10 years) will relapse with distant metastases and most of them will die. Because this dismal prognosis concerns a small number of patients, T1N0 BC have been rarely studied. The aim of this work was to identify the mechanisms of metastatic recurrence in luminal breast cancers T1b-cN0M0 at diagnosis by deciphering characteristics of both epithelial cancer cells and their surrounding tumor microenvironment (TME). Experimental Design: We constituted a cohort of luminal T1b-cN0 BC patients with metastatic recurrence (defined as "cases”) and corresponding "controls" (i. e. patients without metastatic relapse) matched (1:1) to cases on the main known prognostic factors: age, tumor grade and tumor proliferation (assessed by Ki67). Results: We found that properties in both epithelial compartment and TME are indicative of relapse in early luminal breast cancers. In univariate analysis, the loss of differentiation (assessed by the reduced expression of CDH1/E-cadherin) in cancer cells is associated with recurrence, as also predicted by high ROR score using ProsignaTM test. In TME, quantitative and qualitative immunohistochemical analyzes reveals that “cases” are characterized by a significant decrease in CD4+ T lymphocytes and an accumulation of a particular subset of Cancer Associated Fibroblasts (CAF-S1) compared to “controls”, without any other association of T lymphocyte subtypes, B lymphocytes, macrophages or dendritic cells. In multivariate analysis, TME features, in particular CAF-S1 enrichment, remain significantly associated with recurrence, which demonstrates their biological and clinical relevance. Finally, by performing functional analyses, we demonstrated that CAF-S1 pro-metastatic properties are -at least in part- mediated by CDH11/Osteoblast cadherin, consistent with the fact that the bones are a major site of metastases in these patients. Conclusions: Distant recurrence in early luminal BC is strongly associated with TME features, such as the presence of CAF-S1 and their expression of CDH11. This is independent of tumor cells and represents a new prognostic factor of distant relapse in early luminal BC patients. This could justify targeted therapies against CAF-S1 or CDH11 in these cases
Pålsson, Birger. "Tumour marker CA-50 in pancreatic cancer." Lund : Dept. of Surgery, Lund University, 1993. http://catalog.hathitrust.org/api/volumes/oclc/38154714.html.
Повний текст джерелаMuller, Laure. "Modélisation et traitement du signal de rétrodiffusion lumineuse dans les tissus vivants appliques à la détection de bas niveaux de saturation en oxygène : contribution à l'optimisation de la dosimétrie en thérapie photodynamique anticancéreuse." Vandoeuvre-les-Nancy, INPL, 1994. http://www.theses.fr/1994INPL120N.
Повний текст джерелаPayne, Kyle K. "Immunotherapy of Cancer: Reprogramming Tumor/Immune Cellular Crosstalk to Improve Anti-Tumor Efficacy." VCU Scholars Compass, 2015. http://scholarscompass.vcu.edu/etd/3939.
Повний текст джерелаFumagalli, Debora. "Evaluation of tumor heterogeneity in breast cancer." Doctoral thesis, Universite Libre de Bruxelles, 2016. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/229735.
Повний текст джерелаBreast cancer still represents the most frequently diagnosed cancer and the leading cause of cancer-related mortality in women. Death is usually caused by the development of resistance to treatments and the resulting metastatic spread of the disease. Despite the clinical relevance, little is known about the molecular complexity of the disease and its dynamics.Breast tumor heterogeneity has been observed at the level of the histology and the natural history of the disease for a long time, and these differences have served as the basis for disease classification. With the advent of high-throughput technologies, such as gene expression microarrays and massively parallel sequencing, this classification has been refined and a previously unknown genetic complexity has been revealed. Studies implementing these technologies have shown that molecular dif¬ferences exist not only between different breast cancer patients (inter-tumor heterogeneity), but also within the same patient (intra-tumor heterogeneity). Furthermore, intra-tumor heterogeneity could occur either between different regions of a tumor (spatial intra-tumor heterogeneity), or as the result of the molecular evolu¬tion of a tumor over time (temporal intra-tumor heterogeneity). This complexity might have a profound impact on the way breast cancer patients are managed and treated. The research work that I carried out in the Breast Cancer Translational Research Laboratory under the direction of Prof Christos Sotiriou had two main aims. The first was to determine the extent and the clinical implications of intra-tumor heterogeneity in two common clinical scenarios, namely: multifocal breast cancers (MFBCs) and metastatic ER positive/HER2 negative breast cancers. The second was to investigate the potential impact of yet poorly characterized phenomenon, such as RNA editing, in determining inter-tumor heterogeneity. For this purpose, I have conducted three main projects, which resulted in three manuscripts.We showed that:1) The lesions of all the investigated MFBCs shared a common origin. Despite this, and despite having similar pathological features, in up to a third of the patients the lesions of the same MFBC didn’t share any substitution/indels, and inter-lesion heterogeneity was observed for oncogenic mutation(s) in genes such as PIK3CA, TP53, GATA3, and PTEN; 2) When focusing on a defined number of cancer-associated genes, a substantial concordance for mutations and copy number aberrations could be found between primary and matched metastatic lesions of ER positive/HER2 negative breast cancers. Differences between matched pairs could however be found for the level of expressions of few genes. In primary lesions, only the expression levels of few genes and high FGFR1 amplification levels were associated with OS;3) A-to-I RNA editing is a pervasive source of transcriptome variation in breast cancer. In breast and potentially all cancers, A-to-I editing is mainly controlled by two factors, namely 1q amplification and inflammation, both of which are highly prevalent among human cancers. The wide-spread editing observed, in combination with the conservation of editing sites detected across tissues and patients, suggests that there might be clinical and therapeutic implications for a wide range of cancer patients.Our results suggest both that a thorough molecular characterization of multifocal and metastatic breast cancers is important to appreciate their genomic complexity, and that in breast cancer research more relevance should be given to RNA editing, a yet poorly investigated phenomenon that has the potential to impact the development and the evolution of the disease.
Doctorat en Sciences médicales (Médecine)
info:eu-repo/semantics/nonPublished
Книги з теми "Cancer tumer"
Janes-Hodder, Honna. Childhood cancer: A parent's guide to solid tumor cancers. 2nd ed. Beijing: O'Reilly, 2002.
Знайти повний текст джерела1935-, Sell Stewart, ed. Serological cancer markers. Totowa, N.J: Humana Press, 1992.
Знайти повний текст джерела1954-, Srivastava Sudhir, ed. Early detection of cancer: Molecular markers. Armonk, N.Y: Futura Pub. Co., 1994.
Знайти повний текст джерелаH, Goldfarb Ronald, ed. Brain tumor invasiveness. Dordrecht: Kluwer Academic, 1994.
Знайти повний текст джерелаF, Oettgen Herbert, ed. Gangliosides and cancer. Weinheim, Federal Republic of Germany: VCH Verlagsgesellschaft, 1989.
Знайти повний текст джерелаT, Garrett Carleton, and Sell Stewart 1935-, eds. Cellular cancer markers. Totowa, N.J: Humana Press, 1995.
Знайти повний текст джерелаMarry M. van den Heuvel-Eibrink, ed. Wilms Tumor. Brisbane, Australia: Codon Publications, 2016.
Знайти повний текст джерелаTumor models in cancer research. 2nd ed. New York: Humana Press, 2011.
Знайти повний текст джерелаTeicher, Beverly A. Tumor Models in Cancer Research. New Jersey: Humana Press, 2001. http://dx.doi.org/10.1385/1592591000.
Повний текст джерелаPag�, Michel. Tumor Targeting in Cancer Therapy. New Jersey: Humana Press, 2002. http://dx.doi.org/10.1385/1592591671.
Повний текст джерелаЧастини книг з теми "Cancer tumer"
Camelo, Felipe, and Anne Le. "The Intricate Metabolism of Pancreatic Cancers." In The Heterogeneity of Cancer Metabolism, 77–88. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65768-0_5.
Повний текст джерелаvan Herpen, Carla M. L. "Patients with Rare Head Neck Cancers: Do They Need a Different Approach?" In Critical Issues in Head and Neck Oncology, 309–15. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_20.
Повний текст джерелаZarisfi, Mohammadreza, Tu Nguyen, Jessie R. Nedrow, and Anne Le. "The Heterogeneity Metabolism of Renal Cell Carcinomas." In The Heterogeneity of Cancer Metabolism, 117–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65768-0_8.
Повний текст джерелаFerrari, Marco, Nausica Montalto, and Piero Nicolai. "Novel Approaches in Surgical Management: How to Assess Surgical Margins." In Critical Issues in Head and Neck Oncology, 95–110. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_7.
Повний текст джерелаWatson, Geoffrey Alan, Kirsty Taylor, and Lillian L. Siu. "Innovation and Advances in Precision Medicine in Head and Neck Cancer." In Critical Issues in Head and Neck Oncology, 355–73. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_24.
Повний текст джерелаParker, Nicole N., and Dietmar W. Siemann. "The Microenvironment in Cancer." In Tumor Microenvironment, 1–6. Chichester, UK: John Wiley & Sons, Ltd, 2010. http://dx.doi.org/10.1002/9780470669891.ch1.
Повний текст джерелаImai, Kohzoh, and Toshiro Sugiyama. "Tumor Markers." In Gastric Cancer, 218–30. Tokyo: Springer Japan, 1993. http://dx.doi.org/10.1007/978-4-431-68328-5_16.
Повний текст джерелаParmiani, G. "Tumor Immunology." In Cancer Metastasis, 226–29. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74236-1_32.
Повний текст джерелаWalser, Tonya C., Jane Yanagawa, Edward Garon, Jay M. Lee, and Steven M. Dubinett. "Tumor Microenvironment." In Lung Cancer, 27–69. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_2.
Повний текст джерелаRyu, Ji Kon. "Tumor Markers." In Pancreatic Cancer, 89–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-47181-4_6.
Повний текст джерелаТези доповідей конференцій з теми "Cancer tumer"
Sztejnberg, Manuel L., and Tatjana Jevremovic. "Advanced Application of BNCT in Advanced Cancers." In 17th International Conference on Nuclear Engineering. ASMEDC, 2009. http://dx.doi.org/10.1115/icone17-75906.
Повний текст джерелаStokol, Tracy, Mandy B. Esch, Nozomi Nishimura, Chris Schaffer, Janelle L. Daddona, David J. Post, and Dhruv P. Desai. "Little Channels, Big Disease: Using Microfluidics to Investigate Cancer Metastasis." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58298.
Повний текст джерелаSoucy, P., W. Ehringer, C. Klinge, H. Frieboes, and A. Gobin. "An Innovative Approach for Curcumin Delivery for Breast Cancer Using Albumin Nanoparticles." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93295.
Повний текст джерелаLima, Beatriz Alves, Andressa da Silva Pereira, Bruna Alves Lima, Diana Gonçalves Lima, Leonardo Ferreira Pucci, Renato Moraes Ferreira, Tiago Castro Ferreira, and Henrique Ferreira Pucci. "PREDICTORS OF BREAST CANCER PROGNOSIS BASED ON TUMOR BIOMARKERS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2022.
Повний текст джерелаQueiroz, Andrei Alves de, Debora Garcia y. Narvaiza, Ana Maria Kemp, and Gisele Tolaini Gomes Pereira. "LOBULAR BREAST CARCINOMA: THE RISK FOR CONTRALATERAL BREAST IS NOT PERMANENT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1028.
Повний текст джерелаZielinski, Rachel, Cosmin Mihai, and Samir Ghadiali. "Multi-Scale Modeling of Cancer Cell Migration and Adhesion During Epithelial-to-Mesenchymal Transition." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53511.
Повний текст джерелаPatel, Sagar S., Ramesh Natarajan, and Rebecca L. Heise. "Mechanotransduction of Primary Cilia in Lung Adenocarcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80435.
Повний текст джерелаMcClain, Jacob, Sara L. Tuell, and Susan N. Thomas. "Tumors Change the Elastic and Viscoelastic Properties of Draining Lymph Node Tissues." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14419.
Повний текст джерелаRabin, Yoed, Thomas B. Julian, Peter Olson, Michael J. Taylor, and Norman Wolmark. "Cryosurgery for Breast Malignancies: Apparatus and Techniques." In ASME 1999 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1999. http://dx.doi.org/10.1115/imece1999-0585.
Повний текст джерелаMelo, Maria Eduarda Bernardino Martins, Gabriela Prado Lopes, Darley Lima Ferreira Filho, Irnanda Layanna Gomes Oliveira, and Maria Eduarda Vasconcelos Florêncio Cavalcanti. "MALE BILATERAL BREAST CANCER: CASE REPORT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1077.
Повний текст джерелаЗвіти організацій з теми "Cancer tumer"
Wang, Ying yuan, Zechang Chen, Luxin Zhang, Shuangyi Chen, Zhuomiao Ye, Tingting Xu, and Yingying Zhang c. A systematic review and network meta-analysis: Role of SNPs in predicting breast carcinoma risk. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0092.
Повний текст джерелаDeng, Chun, Zhenyu Zhang, Zhi Guo, Hengduo Qi, Yang Liu, Haimin Xiao, and Xiaojun Li. Assessment of intraoperative use of indocyanine green fluorescence imaging on the number of lymph node dissection during minimally invasive gastrectomy: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0062.
Повний текст джерелаKengsakul, Malika, Gatske Nieuwenhuyzen – de Boer, and Heleen van Beekhuizen. Radiological factors associated with residual disease after cytoreductive surgery for advanced ovarian cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0059.
Повний текст джерелаLi, Zhenqi, Guangfu Zhang, Jia Liu, and Xiaolin Li. Risk factors for gallbladder Cancer:A meta-analysis based on nearly a decade of research. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0065.
Повний текст джерелаShyam, E., and P. Reddy. Tumor Suppressors and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2001. http://dx.doi.org/10.21236/ada403397.
Повний текст джерелаShyam, E., and P. Reddy. Tumor Suppressors and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada412779.
Повний текст джерелаLin, Yawei, Yi Chen, Rongrong Liu, and Baohua Cao. Effect of exercise on rehabilitation of breast cancer surgery patients: A systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0065.
Повний текст джерелаTenniswood, Martin P. Apoptosis and Tumor Progressionin Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, February 2005. http://dx.doi.org/10.21236/ada443063.
Повний текст джерелаUribe Ruíz, Natalia Andrea, and Roberto Benavides Arenas. Enfoque del paciente con cáncer primario de origen desconocido. Facultad de Medicina Universidad de Antioquia, August 2023. http://dx.doi.org/10.59473/medudea.pc.2023.17.
Повний текст джерелаZHAO, JIE, LIANHUA YE, WEI WANG, YANTAO YANG, ZHENGHAI SHEN, and SUNYIN RAO. Surgical Prognostic Factors of Second Primary Lung Cancer: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0047.
Повний текст джерела